Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Corneal cross-linking for the treatment of progressive keratoconus

Poster Details

First Author: E.Vounotrypidis GERMANY

Co Author(s):    W. Mayer   J. Rüping   E. Messmer   K. Eibl   D. Kook  

Abstract Details



Purpose:

To evaluate clinical and topographical changes after corneal crosslinking (CXL) in patients with progressive keratoconus.

Setting:

Department of Ophthalmology, Ludwig-Maximilian-University Munich, Germany

Methods:

Retrospective case study. 65 eyes of 51 patients with progressive keratoconus were treated with corneal collagen crosslinking using standard protocol (IROC). Follow up was at least 12 months. 33 fellow eyes served as controls. Indication was either progression of K-values, or thinning of the minimum corneal thickness. UDVA, CDVA, IOP, corneal topography and pachymetry (Pentacam), slit-lamp examination and endothelial cell count were performed pre-, 3, 6 and 12 months postoperatively.

Results:

Patient sex was 38 male and 13 female, mean age was 30 years. The statistical analysis showed a flattening of the cornea in the CXL group combined with reduction of the K values of almost 1 dpt (mean) and CDVA improvement of 0,1 LogMAR. The mean thinnest corneal thickness reduced from 450ṁm (mean) to 437 ṁm (mean), while high order aberrations and posterior elevation decreased partly significantly. No significant changes of the endothelial cell count were observed in the CXL group (p>0.05). In the control group of the fellow eyes, K-values, thinnest corneal thickness, high order aberrations, posterior elevation and endothelial cell count remained unchanged (p>0.05).

Conclusions:

Corneal crosslinking shows positive impact regarding the corneal topography and visual acuity. Considering these advantages together with the lack of serious complications CXL is a safe and efficient treatment of progressive keratoconus.

Financial Disclosure:

NONE

Back to previous